September 26th, 2017
Management and employees of Immunovia subscribe for new shares by exercising warrants
Management and employees at Immunovia AB (publ) (”The Company”) have subscribed for 514,000 new shares in Immunovia AB (publ) by exercising 504,000 warrants of series 2014/2017 that were issued during the first quarter of 2014, and 10,000 warrants of series 2015/2017 that were issued during the second quarter of 2015. The new shares will raise a total of SEK 4,923,000 to The Company. The number of shares will increase from 16,474,568 to 16,988,568 and the equity will increase from SEK 823,728.40 to SEK 849,428.40 after registration at Bolagsverket (the Swedish Companies Registration Office).
In order to finance the subscribed shares in The Company, some members of management and some employees have sold shares. Among them are CEO Mats Grahn and CSO Rolf Ehrnström, who have sold 35,636 and 4,847 shares respectively to the price of 98 SEK per share. The excess proceeds from the sale will finance tax on capital gains from the sold shares.
“It is very pleasant to become an even larger shareholder in Immunovia,” commented Mats Grahn, CEO, Immunovia.
For more information, please contact:
Chief Executive Officer, CEO, Immunovia
Immunovia AB was founded in 2007 by investigators from the Department of Immunotechnology at Lund University and CREATE Health, the Center for Translational Cancer Research in Lund, Sweden. Immunovia’s strategy is to decipher the wealth of information in blood and translate it into clinically useful tools to diagnose complex diseases such as cancer, earlier and more accurately than previously possible. Immunovia´s core technology platform, IMMray™, is based on antibody biomarker microarray analysis. The company is now performing clinical validation studies for the commercialization of IMMray™ PanCan-d that could be the first blood based test for early diagnosis of pancreatic cancer. In the beginning of 2016, the company started a program focused on autoimmune diseases diagnosis, prognosis and therapy monitoring. The first test from this program, IMMray™ SLE-d, is a biomarker signature derived for differential diagnosis of lupus, now undergoing evaluation and validation. (Source: www.immunovia.com)
This information is information that Immunovia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, the 26th of September 2017 18:00 CET.
Immunovia’s shares (IMMNOV) are listed on Nasdaq First North in Stockholm and Wildeco is the company’s Certified Adviser. For more information, please visit www.immunovia.com.